Evidence map›Paper›PMID 24875735›Full record

ReviewNature cell biology2014

Oncogenic roles of EMT-inducing transcription factors.

Alain Puisieux, Thomas Brabletz, Julie Caramel

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature cell biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 630 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
630citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

630 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

570 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Alain PuisieuxInserm UMR-S1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69008 Lyon, France; Université Lyon 1, ISPB, F-69000 Lyon, France; and Centre Léon Bérard, F-69008 Lyon, France.
Thomas BrabletzDepartment of General and Visceral Surgery, Comprehensive Cancer Center and BIOSS Centre for Biological Signalling Studies, University of Freiburg Medical Center, Freiburg, Germany, and the German Cancer Consortium (DKTK), Freiburg and German Cancer Research Center (DKFZ), Heidelberg, Germany.
Julie CaramelInserm UMR-S1052, CNRS UMR5286, Centre de Recherche en Cancérologie de Lyon, F-69008 Lyon, France; Université Lyon 1, ISPB, F-69000 Lyon, France; and Centre Léon Bérard, F-69008 Lyon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The plasticity of cancer cells underlies their capacity to adapt to the selective pressures they encounter during tumour development. Aberrant reactivation of epithelial-mesenchymal transition (EMT), an essential embryonic process, can promote cancer cell plasticity and fuel both tumour initiation and metastatic spread. Here we discuss the roles of EMT-inducing transcription factors in creating a pro-tumorigenic setting characterized by an intrinsic ability to withstand oncogenic insults through the mitigation of p53-dependent oncosuppressive functions and the gain of stemness-related properties.

Indexed as

Epithelial-Mesenchymal TransitionAnimalsCell DifferentiationCell Transformation, NeoplasticGene Expression Regulation, NeoplasticHumansNeoplasm InvasivenessNeoplasmsNeoplastic Stem CellsOncogene ProteinsSignal TransductionTranscription FactorsTumor MicroenvironmentTumor Suppressor Protein p53Oncogene ProteinsTranscription FactorsTumor Suppressor Protein p53

Identifiers

PMID24875735

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.